Myovant Sciences Stock Price, News & Analysis (NYSE:MYOV)

$12.96 -0.43 (-3.21 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$13.39
Today's Range$12.94 - $13.89
52-Week Range$9.92 - $18.85
Volume24,673 shs
Average Volume56,896 shs
Market Capitalization$819.06 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Myovant Sciences (NYSE:MYOV)

Myovant Sciences logoMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.


Industry, Sector and Symbol:
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NYSE:MYOV
  • Previous Symbol: NASDAQ:MYOV
  • CUSIP: N/A
  • Web: www.medite-group.com
Debt:
  • Current Ratio: 9.27%
  • Quick Ratio: 9.27%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $2.77 per share
  • Price / Book: 4.68
Profitability:
  • Trailing EPS: ($1.41)
  • Net Income: ($83,440,000.00)
  • Return on Equity: -49.91%
  • Return on Assets: -45.87%
Misc:
  • Employees: 36
  • Outstanding Shares: 60,990,000
 
Frequently Asked Questions for Myovant Sciences (NYSE:MYOV)

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Where is Myovant Sciences' stock going? Where will Myovant Sciences' stock price be in 2017?

6 equities research analysts have issued 12-month price objectives for Myovant Sciences' stock. Their forecasts range from $17.00 to $25.00. On average, they expect Myovant Sciences' stock price to reach $20.00 in the next twelve months. View Analyst Ratings for Myovant Sciences.

What are Wall Street analysts saying about Myovant Sciences stock?

Here are some recent quotes from research analysts about Myovant Sciences stock:

  • 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (11/17/2017)
  • 2. Cowen and Company analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017)

Who are some of Myovant Sciences' key competitors?

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:

  • Lynn Seely M.D., Principal Executive Officer, Director (Age 58)
  • Frank L. Karbe, Principal Financial, Accounting Officer (Age 48)
  • Marianne L. Romeo, Head, Global Transactions & Risk Management (Age 48)
  • Terrie Curran, Director (Age 48)
  • Keith S. Manchester M.D., Director (Age 47)
  • Vivek Ramaswamy, Director (Age 30)
  • Mark Altmeyer, Independent Director (Age 56)
  • Wayne S. DeVeydt, Independent Director (Age 47)

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Myovant Sciences stock?

Myovant Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include SVF INVESTMENTS (UK) LTD (61.20%), JPMorgan Chase & Co. (0.15%), Point72 Asset Management L.P. (0.13%) and OxFORD Asset Management LLP (0.04%). View Institutional Ownership Trends for Myovant Sciences.

Who sold Myovant Sciences stock? Who is selling Myovant Sciences stock?

Myovant Sciences' stock was sold by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP. View Insider Buying and Selling for Myovant Sciences.

Who bought Myovant Sciences stock? Who is buying Myovant Sciences stock?

Myovant Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and JPMorgan Chase & Co.. View Insider Buying and Selling for Myovant Sciences.

How do I buy Myovant Sciences stock?

Shares of Myovant Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of Myovant Sciences stock can currently be purchased for approximately $12.96.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $819.06 million. The company earns ($83,440,000.00) in net income (profit) each year or ($1.41) on an earnings per share basis. Myovant Sciences employs 36 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 203-318-9709 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Myovant Sciences (NYSE:MYOV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.00 (54.32% upside)
Consensus Price Target History for Myovant Sciences (NYSE:MYOV)
Price Target History for Myovant Sciences (NYSE:MYOV)
Analysts' Ratings History for Myovant Sciences (NYSE:MYOV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingBuy$20.00N/AView Rating Details
10/4/2017JMP SecuritiesReiterated RatingOutperform$23.00 -> $25.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> OutperformHighView Rating Details
11/21/2016Citigroup Inc.Initiated CoverageBuy$17.00N/AView Rating Details
11/21/2016Barclays PLCInitiated CoverageOverweight$18.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Myovant Sciences (NYSE:MYOV)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Myovant Sciences (NYSE:MYOV)
Current Year EPS Consensus Estimate: $-1.54 EPS
Next Year EPS Consensus Estimate: $-1.66 EPS

Dividends

Dividend History for Myovant Sciences (NYSE:MYOV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Myovant Sciences (NYSE MYOV)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Myovant Sciences (NYSE:MYOV)
Latest Headlines for Myovant Sciences (NYSE MYOV)
Source:
DateHeadline
Myovant Sciences (MYOV) & Its Peers Head-To-Head SurveyMyovant Sciences (MYOV) & Its Peers Head-To-Head Survey
www.americanbankingnews.com - November 16 at 7:10 PM
Head to Head Review: Myovant Sciences (MYOV) and Its CompetitorsHead to Head Review: Myovant Sciences (MYOV) and Its Competitors
www.americanbankingnews.com - November 15 at 3:30 PM

Social Media

Financials

Chart

Myovant Sciences (NYSE MYOV) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.